Jiang Han-Yu, Zheng Hui-Min, Xia Cheng, Li Xiang, Wang Gang, Zhao Tong, Cui Xiao-Nan, Wang Ruo-Yu, Liu Ying
Department of Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People's Republic of China.
Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116011, People's Republic of China.
Onco Targets Ther. 2022 Mar 22;15:291-298. doi: 10.2147/OTT.S333233. eCollection 2022.
Hepatocellular carcinoma (HCC) is one of the deadliest cancers in the world with a five-year survival rate of less than 20%. Nonetheless, selecting an appropriate therapeutic agent to inhibit the development of hepatoma cells is still a challenge. Bufalin, a component of the traditional Chinese medicine Chansu, has been shown to inhibit the proliferation, invasion and metastasis of HCC through various signaling pathways. In addition, bufalin and sorafenib demonstrate a synergistic effect in cancer therapeutics. This review highlighted on several focal signaling pathways involved in the inhibitory effects of bufalin on HCC and its synergistic mechanisms with sorafenib. The immunotherapy effect of bufalin has also been discussed as a novel property.
肝细胞癌（HCC）是世界上最致命的癌症之一，五年生存率不到20%。尽管如此，选择合适的治疗药物来抑制肝癌细胞的发展仍然是一项挑战。蟾酥灵是中药蟾酥的一种成分，已被证明可通过多种信号通路抑制肝癌细胞的增殖、侵袭和转移。此外，蟾酥灵和索拉非尼在癌症治疗中显示出协同作用。本文综述了蟾酥灵对肝癌抑制作用及其与索拉非尼协同机制所涉及的几个关键信号通路。蟾酥灵的免疫治疗作用也作为一种新特性进行了讨论。
